Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced toda...
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
Global Blood Therapeutics (GBT) says that on June 1, 2021, the compensation committee of GBT's board granted 11 new employees options to purchase an aggregate of 35,500 shares of the company's common stock at $37.20/share and restricted stock units for an aggregate of 45,410 shares of th...
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m...
SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2021 Virtual Congress ...
Beyond the initial approval, the company is seeking Oxbryta label expansion as well as approval in the European Union. The company is increasing its focus on sickle cell disease by advancing inclacumab into two Phase 3 trials as well as generating proof-of-concept data for GBT-601. ...
Shares of Global Blood Therapeutics (NASDAQ: GBT) were sinking 8% as of 11:14 a.m. EDT on Thursday. The decline came after the company announced its first-quarter results following the market close on Wednesday. Global Blood Therapeutics reported net sales of $39 million in the ...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2021 Earnings Call May 05, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2021 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (GBT) Q1 2021 Results Conference Call May 05, 2021 04:30 PM ET Company Participants Steven Immergut - SVP, Head of Corporate Communications and IR Dr. Ted Love - President and Chief Executive Officer Jeff Farrow - Chief Financial Officer David Johnson - Chief C...
Global Blood Therapeutics (GBT): Q1 GAAP EPS of -$1.21 misses by $0.20.Revenue of $39.04M (+176.5% Y/Y) misses by $3.96M.Shares -2.33%.Press Release For further details see: Global Blood Therapeutics EPS misses by $0.20, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...